GSA Capital Partners LLP Buys New Position in Disc Medicine, Inc. $IRON

GSA Capital Partners LLP purchased a new position in Disc Medicine, Inc. (NASDAQ:IRON) in the second quarter, Holdings Channel.com reports. The fund purchased 16,324 shares of the company’s stock, valued at approximately $1,194,000.

Other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC raised its stake in Disc Medicine by 1,277.1% in the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after buying an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after buying an additional 3,454 shares during the period. Legal & General Group Plc boosted its position in Disc Medicine by 18.0% during the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after acquiring an additional 3,682 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Disc Medicine by 21.6% during the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock worth $891,000 after acquiring an additional 2,983 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Rahul Khara sold 7,500 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the sale, the insider directly owned 52,173 shares of the company’s stock, valued at approximately $3,663,588.06. This represents a 12.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 34,000 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer directly owned 226,064 shares in the company, valued at $15,871,953.44. This trade represents a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 111,516 shares of company stock worth $8,063,979 in the last quarter. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine Trading Up 1.5%

Disc Medicine stock opened at $80.05 on Tuesday. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $74.89 and its two-hundred day simple moving average is $69.89. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a market capitalization of $306.59 million, a price-to-earnings ratio of -12.17 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. As a group, equities analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright raised their target price on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley restated an “overweight” rating and set a $90.00 target price on shares of Disc Medicine in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a research note on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.50.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.